UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

Gut, 2011-04, Vol.60 (4), p.463-472

2011

Volltextzugriff (PDF)

Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow

Biomedicine & pharmacotherapy, 2022-09, Vol.153, p.113380-113380, Article 113380

2022

Volltextzugriff (PDF)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma

PloS one, 2019-01, Vol.14 (1), p.e0210077-e0210077

2019

Volltextzugriff (PDF)

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

Biochimica et biophysica acta. Molecular basis of disease, 2018-04, Vol.1864 (4), p.1335-1344

2018

Volltextzugriff (PDF)

Chronic inflammation in the pathogenesis of benign prostatic hyperplasia

International journal of andrology, 2010-06, Vol.33 (3), p.475-488

2010

Volltextzugriff (PDF)

Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance

The Journal of immunology (1950), 2001-08, Vol.167 (4), p.1945-1953

2001

Volltextzugriff (PDF)

Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model

Journal of endocrinological investigation, 2019-03, Vol.42 (3), p.283-294

2019

Volltextzugriff (PDF)

Cardiomyocytes Induce Endothelial Cells to Trans-Differentiate into Cardiac Muscle: Implications for Myocardium Regeneration

Proceedings of the National Academy of Sciences - PNAS, 2001-09, Vol.98 (19), p.10733-10738

2001

Volltextzugriff (PDF)

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model

Journal of endocrinological investigation, 2019-08, Vol.42 (8), p.951-965

2019

Volltextzugriff (PDF)

Upregulation of MATE-1 transporter by obeticholic acid correlates with increased biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury

Journal of hepatology, 2017, Vol.66 (1), p.S613-S613

2017

Volltextzugriff (PDF)

The Farnesoid-X-Receptor Agonist Obeticholic Acid Further Increases Biliary Excretion of Asymmetric Dimethylarginine during Hepatic Ischemia/Reperfusion Injury

Journal of hepatology, 2016, Vol.64 (2), p.S315-S315

2016

Volltextzugriff (PDF)

OC.06.8 INTEGRATED ANALYSIS OF EFFICACY OF PHASE II AND III DATA OF OBETICHOLIC ACID IN PBC SUBPOPULATIONS BASED ON AGE AND SEX

Digestive and liver disease, 2016-02, Vol.48, p.e93-e94

2016

Volltextzugriff (PDF)

OC.06.1 ANALYSIS OF THE EFFICACY OF OCA IN PRIMARY BILIARY CIRRHOSIS BY VARYING PATIENT DISEASE SEVERITY ACROSS THREE RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALS

Digestive and liver disease, 2016-02, Vol.48, p.e91-e91

2016

Volltextzugriff (PDF)

OC.03.4 EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS: AN ANALYSIS OF THE ITALIAN PATIENTS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY

Digestive and liver disease, 2016-02, Vol.48, p.e81-e81

2016

Volltextzugriff (PDF)

P1155 : FXR Agonism with obeticholic acid may attenuate bone mineral density decrease in subjects with primary biliary cirrhosis

Journal of hepatology, 2015-04, Vol.62, p.S786-S786

2015

Volltextzugriff (PDF)

Increase in transporter MATE-1 expression induced by obeticholic acid correlates with higher biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury

Digestive and liver disease, 2017-02, Vol.49 (1), p.e30-e30

2017

Volltextzugriff (PDF)

Elocalcitol Inhibits Inflammatory Responses in Human Thyroid Cells and T Cells

Endocrinology (Philadelphia), 2008-07, Vol.149 (7), p.3626-3634

2008

Volltextzugriff (PDF)

Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis

Clinical and translational science, 2017-07, Vol.10 (4), p.292-301

2017

Volltextzugriff (PDF)

Interleukin 12 and autoimmune diabetes

Nature genetics, 2001-02, Vol.27 (2), p.131-132

Adorini, Luciano

2001

Volltextzugriff (PDF)

Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis

Journal of cystic fibrosis, 2011-12, Vol.10 (6), p.428-434

2011

Volltextzugriff (PDF)

OC.12.8 LONG-TERM SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS

Digestive and liver disease, 2016-02, Vol.48, p.e117-e118

2016

Volltextzugriff (PDF)

Further increase in biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury by obeticholic acid, a farnesoid-X-receptor agonist

Digestive and liver disease, 2016-02, Vol.48, p.e55-e55

2016

Volltextzugriff (PDF)

Human Bladder as a Novel Target for Vitamin D Receptor Ligands

The journal of clinical endocrinology and metabolism, 2005-02, Vol.90 (2), p.962-972

2005

Volltextzugriff (PDF)

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Gastroenterology (New York, N.Y. 1943), 2013-09, Vol.145 (3), p.574-582.e1

2013

Volltextzugriff (PDF)

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.751-761.e8

2015

Volltextzugriff (PDF)

1 – 25 von 288

Suche als RSS-Feed

Aktive Filter

ThemaImmunology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(193)
Mit Volltextzugriff
(259)

Publikationsform

Artikel
(214)
Buchkapitel
(73)
Reviews
(1)

Sprache

Englisch
(288)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Animals
(105)
Chapter
(80)
Mice
(80)
Science & Technology
(66)
Life Sciences & Biomedicine
(55)
Humans
(54)
Biological And Medical Sciences
(52)
T-Lymphocytes - Immunology
(39)
Fundamental And Applied Biological Sciences. Psychology
(34)
Male
(33)
Female
(29)
Medical Sciences
(25)
Muramidase - Immunology
(25)
Amino Acid Sequence
(19)
Fundamental Immunology
(19)
Endocrinology & Metabolism
(18)
Histocompatibility Antigens Class Ii - Immunology
(17)
Immunobiology
(17)
Mice, Inbred C57bl
(17)
Molecular Sequence Data
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

Chronic inflammation in the pathogenesis of benign prostatic hyperplasia

Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance

Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model

Cardiomyocytes Induce Endothelial Cells to Trans-Differentiate into Cardiac Muscle: Implications for Myocardium Regeneration

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model

Upregulation of MATE-1 transporter by obeticholic acid correlates with increased biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury

The Farnesoid-X-Receptor Agonist Obeticholic Acid Further Increases Biliary Excretion of Asymmetric Dimethylarginine during Hepatic Ischemia/Reperfusion Injury

OC.06.8 INTEGRATED ANALYSIS OF EFFICACY OF PHASE II AND III DATA OF OBETICHOLIC ACID IN PBC SUBPOPULATIONS BASED ON AGE AND SEX

OC.06.1 ANALYSIS OF THE EFFICACY OF OCA IN PRIMARY BILIARY CIRRHOSIS BY VARYING PATIENT DISEASE SEVERITY ACROSS THREE RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALS

OC.03.4 EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS: AN ANALYSIS OF THE ITALIAN PATIENTS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY

P1155 : FXR Agonism with obeticholic acid may attenuate bone mineral density decrease in subjects with primary biliary cirrhosis

Increase in transporter MATE-1 expression induced by obeticholic acid correlates with higher biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury

Elocalcitol Inhibits Inflammatory Responses in Human Thyroid Cells and T Cells

Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis

Interleukin 12 and autoimmune diabetes

Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis

OC.12.8 LONG-TERM SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS

Further increase in biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury by obeticholic acid, a farnesoid-X-receptor agonist

Human Bladder as a Novel Target for Vitamin D Receptor Ligands

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

Aktive Filter

Suchergebnisse filtern